NEW YORK – J Ints Bio said on Monday that it has treated the first patient in its Phase I/II clinical trial of JIN-A02 for advanced, EGFR C797S-mutated non-small cell lung cancer patients.
In the global trial, Seoul-based J Ints Bio is evaluating the safety, pharmacokinetics, and anti-tumor activity of its fourth-generation EGFR tyrosine kinase inhibitor. The agent is designed to inhibit EGFR C797S mutations, which are commonly associated with resistance to earlier EGFR inhibitors including AstraZeneca's Tagrisso (osimertinib). JIN-A02 is also designed to penetrate the blood-brain barrier to target NSCLC central nervous system metastases.
The first patient on the Phase I/II trial was treated at the Severance Hospital in Seoul. J Ints Bio says it will begin enrolling patients at additional clinical sites, including seven more hospitals in Korea, two centers in the US, and one in Thailand.
"We expect the positive results of JIN-A02 in the preclinical studies to translate to positive outcomes for patients in the clinical trial," J Ints Bio CEO Anna Jo said in a statement, adding that the company also hopes to move forward with an orphan drug application.